Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

coronary artery disease - revascularization with drug eluting stent - unparticular patients  


Related trials

SPIRIT IV, 2010 - everolimus ES vs paclitaxel ES

RESOLUTE, 2010 - zotarolimus ES vs everolimus ES

COMPARE, 2009 - everolimus ES vs paclitaxel ES

ISAR-TEST-4, 2009 - sirolimus biodegradable polymer vs sirolimus ES

ZEST (vs SES), 2009 - zotarolimus ES vs sirolimus ES

ENDEAVOR IV, 2009 - zotarolimus ES vs paclitaxel ES

ZEST (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

SPIRIT III, 2008 - everolimus ES vs paclitaxel ES

Costar II, 2008 - CoStar stent vs paclitaxel ES

LEADERS, 2008 - biolimus ES vs sirolimus ES

SORT OUT II, 2008 - sirolimus ES vs paclitaxel ES

Wessely, 2008 - sirolimus ES vs paclitaxel ES

Kochiadakis, 2007 - sirolimus ES vs bare-metal stent

Ortolani et al, 2007 - sirolimus ES vs bare-metal stent

ENDEAVOR II, 2006 - zotarolimus ES vs bare-metal stent

Zhang (SES vs PES), 2006 - sirolimus ES vs paclitaxel ES

SPIRIT II, 2006 - everolimus ES vs paclitaxel ES

REALITY, 2006 - sirolimus ES vs paclitaxel ES

Han, 2006 - sirolimus ES vs paclitaxel ES

ISAR-TEST-1, 2006 - sirolimus ES vs paclitaxel ES

FUTURE II, 2006 - everolimus ES vs bare-metal stent

ENDEAVOR III, 2006 - zotarolimus ES vs sirolimus ES

TAXi, 2005 - sirolimus ES vs paclitaxel ES

BASKET (vs paclitaxel), 2005 - sirolimus ES vs paclitaxel ES

Pache et al, 2005 - sirolimus ES vs bare-metal stent



See also:

  • All coronary artery disease clinical trials
  • All clinical trials of revascularization with drug eluting stent
  • All clinical trials of sirolimus ES
    		•  

    Wessely study, 2008

    Treatments

    Studied treatment rapamycin polymer-coated drug-eluting stent
    Control treatment paclitaxel polymer-coated drug-eluting stent

    Patients

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding NA
    Follow-up duration 9 months
    Number of centre 1
    Geographic area Germany
    Hypothesis Superiority
    Primary endpoint none


    Results

    No results available for this trial - no clinical endpoint reported



    Reference(s)

    Trials register # NA
    • Wessely R, Kastrati A, Mehilli J, Dibra A, Pache J, Schmig A. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design.. Eur Heart J 2007 Nov;28:2720-5
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend